Infinity Pharmaceuticals Inc (INFI.O) Key Developments | Reuters.com
Edition:
United States

Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

1.32USD
24 Jun 2016
Change (% chg)

$0.02 (+1.54%)
Prev Close
$1.30
Open
$1.27
Day's High
$1.34
Day's Low
$1.24
Volume
2,122,192
Avg. Vol
1,001,574
52-wk High
$11.71
52-wk Low
$1.24

Latest Key Developments (Source: Significant Developments)

Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln
Tuesday, 14 Jun 2016 06:39am EDT 

Infinity Pharmaceuticals Inc : Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016 . Expects to incur total restructuring costs ranging from approximately $6 to $8 million . Expects to record a majority of restructuring charges as research and development expenses during three months ended june 30, 2016 . Currently expects $5 million in future cash outlays related to severance, benefits and related costs .Continuing to review potential impact of restructuring, unable to estimate any additional restructuring costs or charges at this time.  Full Article

Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm)
Tuesday, 14 Jun 2016 05:45am EDT 

Infinity Pharmaceuticals Inc : Majority of reported side effects were reversible and clinically manageable. . Infinity Pharmaceuticals Inc says updated 2016 financial guidance to be provided following resolution of strategic activities . Previous financial guidance for 2016 should no longer be relied upon . Investigational, oral, dual inhibitor of phosphoinositide-3-kinase (pi3k)-delta and pi3k-gamma met primary endpoint . Undertaking strategic restructuring that will close down its discovery research organization, or 21 percent of workforce . Infinity Pharmaceuticals Inc says previous financial guidance for 2016 should no longer be relied upon . Duvelisib demonstrated overall response rate (ORR) of 46 percent, among 129 patients with iNHL . Abbvie, co have also agreed to pause ABBVIE-sponsored phase 1b/2 study evaluating duvelisib in combination with venetoclax . Hoped treatment with duvelisib as monotherapy would have provided larger clinical benefit for advance indolent non-hodgkin lymphoma .Infinity reports topline results from DYNAMO(tm), a phase 2 monotherapy study of investigational molecule duvelisib in refractory indolent non-hodgkin lymphoma.  Full Article

Infinity Pharmaceuticals Inc reaffirms FY 2016 guidance
Tuesday, 23 Feb 2016 04:01pm EST 

Infinity Pharmaceuticals Inc:Expects revenue for FY 2016 to range from $225 million to $245 million.Expects net income for FY 2016 to range from $15 million to $35 million.  Full Article

Infinity Pharmaceuticals Inc gives FY 2016 guidance
Monday, 11 Jan 2016 08:01am EST 

Infinity Pharmaceuticals Inc:Expects revenue for FY 2016 to range from $225 million to $245 million.Expects net income for 2016 to range from $15 million to $35 million.  Full Article

Infinity Pharmaceuticals Inc gives FY 2015 guidance; revenue guidance below analysts' estimates
Thursday, 5 Nov 2015 04:05pm EST 

Infinity Pharmaceuticals Inc:Expects FY 2015 revenue to range from $100 million to $120 million.Expects FY 2015 net loss to range from $125 million to $145 million.FY 2015 revenue of $127 million and net income of $(134) million - Thomson Reuters I/B/E/S.  Full Article

Infinity Pharmaceuticals Inc Reports Preclinical Data for Duvelisib Demonstrating Synergy
Tuesday, 26 May 2015 08:00am EDT 

Infinity Pharmaceuticals Inc:Says new preclinical data for duvelisib (IPI-145), an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.Says In vitro studies demonstrated synergy with standard-of-care therapies and emerging agents in development for hematologic malignancies, including duvelisib in combination with venetoclax, in combination with ibrutinib and in combination with dexamethasone.Says Additionally, in preclinical studies with each of these three combinations, significant inhibition of lymphoma tumor growth was observed compared to each of these agents alone.  Full Article

Infinity Pharmaceuticals Inc reaffirms FY 2015 guidance - Conference Call
Tuesday, 24 Feb 2015 04:30pm EST 

Infinity Pharmaceuticals Inc:Says in Jan., it provided financial guidance for 2015, which remains unchanged.Expects revenue for FY 2015 to range from $105 million to $125 million.Expects net loss for FY 2015 to range from $190 million to $210 million.  Full Article

Infinity Pharmaceuticals Inc gives FY 2015 guidance; net income guidance below analysts' estimates
Monday, 12 Jan 2015 08:00am EST 

Infinity Pharmaceuticals Inc:Expects FY 2015 revenue to range from $105 million to $125 million.Expects FY 2015 net loss to range from $190 million to $210 million.FY 2015 revenue of $105 million and net income of $(154) million - Thomson Reuters I/B/E/S.  Full Article

Infinity Pharmaceuticals announces topline results from phase 2 study of Duvelisib
Thursday, 8 Jan 2015 06:50am EST 

Infinity Pharmaceuticals Inc:Says ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) did not meet its primary endpoint.The primary endpoint was the ACR20 response rate at 12 weeks, which is defined as the proportion of patients who achieve at least a 20 percent improvement in American College of Rheumatology (ACR) response criteria after 12 weeks of study treatment.Infinity will not proceed with any further clinical development of its PI3K inhibitors in rheumatoid arthritis.  Full Article

Infinity Pharmaceuticals Inc reports new results from Phase 1 Study of Investigational Oncology Compound Duvelisib
Tuesday, 9 Dec 2014 11:30am EST 

Infinity Pharmaceuticals Inc:Reports updated data from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a fatal type of blood cancer.In study, duvelisib demonstrated an overall response rate of 72 percent, including a 33 percent complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies.In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.  Full Article

BRIEF-Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln

* Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016